Lab fo Dr. Ayad Jaffa

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Link to Dr.Ja​ffa​​'s​ FMIS Profile

​​​​​​Research Area

Research program in my laboratory is translational in nature and is focused on elucidating the genetic, molecular and cellular determinants that foster the development of diabetic vascular complications. Over the years my laboratory has contributed significantly too much of our understanding of the involvement of the kallikrein-kinin system (KKS) in the pathogenesis of diabetic renal and vascular disease, uncovering novel mechanisms of receptor activation, signal transmission and receptor cross talk and heterodimerization.

Research Focus

  • Biomarkers of diabetic complications (Diabetic Nephropathy, Atherosclerosis and Cardiovascular Disease).
  • Growth factors and signal transduction mechanisms
  • Cross-talk between G-protein coupled receptors and tyrosine kinase receptors
  • G-Protein coupled receptor heterodimerization and down-stream signals
  • Proteome signature of diabetic complications

Selected Publications

Plasma connective tissue growth factor levels predict myocardial infarction in the Veterans Affairs Diabetes Trial (VADT) cohort
Kelly J Hunt, Miran A Jaffa, Sara M Garrett, Deirdre K Luttrell, Kenneth E Lipson, Maria F Lopes-Virella, Louis M Luttrell, Ayad A Jaffa
Diabetes Care 41:840-846, 2018.

Proteome profiling in the aorta and kidney of type 1 diabetic rats.
Al Hariri M, Elmedawar M, Zhu R, Jaffa MA, Zhao J, Mirzaei P, Ahmed A, Kobeissy F, Ziyadeh FN, Mechref Y, Jaffa AA
PLoS One. Nov 9;12:e0187752. 2017

Multivariate Generalized Linear Mixed Models With Random Intercepts To Analyze Cardiovascular Risk Markers in Type-1 Diabetic Patients.
Jaffa MA, Gebregziabher M, Luttrell DK, Luttrell LM, Jaffa AA
J Appl Stat. 43(8):1447-1464, 2016

Plasma Prekallikrein is Associated with Carotid Intima-Media Thickness in Type 1 Diabetes.
Jaffa MA, Luttrell D, Schmaier AH, Klein RL, Lopes-Virella M, Luttrell LM, Jaffa AA
Diabetes, 65(2):498-502, 2016

The arrestin-selective antagonist AT1 receptor agonist Sar-Ile4-Ile8-AngII negatively regulates B2-receptor signaling via AT1-B2 receptor heterodimers.​
Wilson PC, Lee MH, Appleton KM, El-Shewy HM, Morinelli TA, Peterson YK, Luttrell LM,​ Jaffa AA
J Biol Chem 288 (26):18872-84 2013